August 2026 Options Now Available For Baxter International (BAX)

BAX is trading at $19.23 and Stock Options Channel highlights two income strategies: selling a $17.50 put (bid $0.35) would obligate purchase at $17.50 with an effective cost basis of $17.15 and represents a 2.00% return (2.97% annualized); the put is ~9% out-of-the-money with a modeled 68% chance to expire worthless. Alternatively, selling a $20.00 covered call (bid $0.75) against shares bought at $19.23 would yield a 7.90% total return if called at the August 2026 expiry; that call is ~4% out-of-the-money with a 45% modeled chance to expire worthless and would provide a 3.90% premium boost (5.79% annualized). Implied volatilities are ~51% for the put and 50% for the call versus a 12-month trailing volatility of 45%.

Analysis

Market structure: Option sellers and yield-focused investors directly benefit from BAX option premiums (put $17.50 bid $0.35; call $20 bid $0.75) because implied vol (50–51%) modestly exceeds realized (45%), creating a small income edge. Equity holders face capped upside if they engage covered-call strategies (max ~7.9% to $20 by Aug‑2026) and face full downside if adverse clinical/regulatory news hits. Cross-asset impact is minimal at scale, though a sharp adverse event would widen credit spreads in healthcare names and lift rates on short-dated hedges; a volatility shock would bid up VIX/med‑tech skews by 5–15 vol points.

Risk assessment: Tail risks include FDA recalls, reimbursement cuts, or supply-chain shocks that could cause >30% drawdowns; these are low probability but high impact for put-sellers. In the immediate term (days–weeks) option premium decay (theta) favors sellers; short term (months) catalysts (earnings, approvals) can swing IV +/-10 vol; long term (quarters–years) secular pressure on device pricing or margin mix matters. Hidden dependencies: a small operational hiccup can compress free cash flow and trigger outsized multiple contraction given med‑tech multiples; watch dealer inventories and hospital purchasing cycles as second-order demand signals.

Trade implications: Direct plays: use small, defined-risk income trades — sell Aug‑2026 $17.50 puts to establish a $17.15 cost basis (premium $0.35) sized to 1–2% portfolio exposure, or buy BAX and write $20 Aug‑2026 calls for a 3–4% carry. Risk-managing alternatives: convert naked put sell into a $17.50/$15.00 put debit spread to cap downside (max loss = $2.50 - net credit). Enter within 10 trading days to capture current premiums, and tighten/close if IV compresses >5 vol points or underlying moves >8% from $19.23.

Contrarian angles: The market is focused on yield (YieldBoost 2.0–3.9%) and understates assignment pain and binary clinical/regulatory risk; IV is only modestly rich so selling is not free. The trade is underdone relative to historical buy‑write outcomes — buy‑write typically underperforms in large rallies (>20%) so cap your allocation to avoid missing multi-quarter upside. Unintended consequence: widespread put-selling could create concentrated ownership at low strikes, amplifying sell pressure into bad news and liquidity squeezes; plan defined protections (verticals or collars).

Key Decisions for Investors

• Sell-to-open BAX Aug‑2026 $17.50 puts (collect ~$0.35) sized so that full assignment equals 1–2% of portfolio value (target cost basis $17.15). Risk rules: buy-to-close if BAX > $21 (up ~9%) or if IV compresses by >5 vol points; limit maximum notional per account to preserve diversification.
• Buy-write: establish a 1–3% long position in BAX at market (~$19.23) and sell Aug‑2026 $20 calls (receive ~$0.75). Exit/roll rules: if BAX > $20 by July 2026, roll up to $22 strike or close for target ~8% return; if BAX < $17, buy back calls and consider switching to a $17.50/$15 put spread to reduce downside.
• Defined-risk alternative: sell Aug‑2026 BAX $17.50/$15.00 put verticals (sell $17.50, buy $15) sized to 0.5–1% portfolio to cap max loss (width $2.50 less net credit). Use this if you want income with capped tail risk; close if IV falls >6 vol points or stock gaps outside strikes on earnings/announcement.
• Relative-value: if concerned about BAX idiosyncratic risk, go neutral by pairing a small (1%) short BAX vs long MDT (Medtronic) of equal beta for 3–6 months — hedge broad med‑tech exposure while expressing relative-quality view. Close the pair on FDA/regulatory headlines or if relative performance diverges >8%.